POM-V Prescription Required

Zuprevo 40 mg/ml Solution for Injection for Pigs

Active ingredient: Tildipirosin

Form

Injection

Species

Pigs

Manufacturer

MSD Animal Health UK Limited

VMD MA No.

01708/5061

What it's used for

Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Glaesserella para...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Tildipirosin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Zuprevo 40 mg/ml Solution for Injection for Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Treatment and metaphylaxis of swine respiratory disease (SRD) associated with
Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Glaesserella parasuis
and Pasteurella multocida.
The presence of the disease in the group must be established before the product is
used.

Do not use in cases of hypersensitivity to macrolide antibiotics or to any of the
excipients.
Do not administer intravenously.
Do not administer simultaneously with other macrolides or lincosamides (see section
4.8).

Pigs:
Very common
(>1 animal / 10 animals
treated):
Immediate pain upon injection, Injection site
swelling
,
Injection site reaction
Rare
(1 to 10 animals / 10,000
animals treated):
Anaphylaxis
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Lethargy
1
may be present up to 6 days post treatment
pathomorphological, resolved completely within 21 days
may be fatal
has been observed in piglets and is transient
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

In line with responsible use principles, metaphylactic use of the veterinary medicinal
product is only indicated in severe outbreaks of SRD caused by the indicated
pathogens. Metaphylaxis implies that clinically healthy animals in close contact with
diseased animals are administered the veterinary medicinal product at the same time
as the treatment of the clinically diseased animals, to reduce the risk for development
of clinical signs.

Issued: January 2024
AN: 03744/2022
The efficacy of metaphylactic use of the veterinary medicinal product was
demonstrated in a placebo controlled multi-centre field study, when outbreak of
clinical disease was confirmed (i.e. animals in at least 30% of the pens sharing the
same airspace showed clinical signs of SRD, including at least 10% animals per pen
within 1 day; or 20% within 2 days or 30% within 3 days). Following metaphylactic
use, approximately 86% of the healthy animals remained free of clinical signs of
disease (as compared to approximately 65% of animals in the untreated control
group).
There is cross resistance with other macrolides.

Special precautions for use in animals
Use of the product should be based on identification and susceptibility testing of the
target pathogen(s). If this is not possible, therapy should be based on
epidemiological information and knowledge of susceptibility of the target pathogens
at farm level, or at local/regional level.
Use of the product should be in accordance with official, national and regional
antimicrobial policies.
Administer strictly intramuscularly. Special attention should be paid to using the
appropriate injection site and to use the appropriate needle size and length (adjusted
to the size and weight of animal) according to good veterinary practice.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
People with known hypersensitivity to tildipirosin should avoid contact with the
veterinary medicinal product.
Special caution should be taken to avoid accidental self-injection, as toxicology
studies in laboratory animals showed cardiovascular effects after intramuscular
administration of tildipirosin. In case of accidental self-injection, seek medical advice
immediately and show the package leaflet or the label to the physician.
Do not use in automatically powered syringes which have no additional protection
system.
Tildipirosin may cause sensitisation by skin contact. If accidental skin exposure
occurs, wash the skin immediately with soap and water. If accidental eye exposure
occurs, flush eyes immediately with clean water.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
Other precautions
Not applicable.

Issued: January 2024
AN: 03744/2022

The product should not be administered with antimicrobials with a similar mode of
action such as other macrolides or lincosamides. Please also refer to sections 4.3
and 4.4.

Do not store above 25 °C.

Meat and offal: 9 days.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.